ENANTA PHARMACEUTICALS, INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ENANTA PHARMACEUTICALS, INC (ENTA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.68M, a 11.83% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.75M, a 20.05% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $3.81M, a 32.76% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.18M, a 22.89% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $18.57M, a 30.71% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $26.80M, a 5.04% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $28.22M, a 4.62% increase from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $26.97M, a 28.48% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.68M 10-Q · filed 2026-08-12 | $7.43M derived: sum of 2 quarters · filed 2026-08-12 | $11.24M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2026-03-31 | $3.75M 10-Q · filed 2026-08-12 | $7.56M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $3.81M 10-Q · filed 2026-08-12 | |||
| 2025-09-30 | $18.57M 10-K · filed 2025-11-19 | |||
| 2025-06-30 | $4.18M 10-Q · filed 2026-08-12 | $8.87M derived: sum of 2 quarters · filed 2026-08-12 | $14.53M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $4.69M 10-Q · filed 2026-08-12 | $10.35M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2024-12-31 | $5.67M 10-Q · filed 2026-08-12 | |||
| 2024-09-30 | $26.80M 10-K · filed 2025-11-19 | |||
| 2024-06-30 | $5.42M 10-Q · filed 2025-08-13 | $10.98M derived: sum of 2 quarters · filed 2025-08-13 | $19.08M derived: sum of 3 quarters · filed 2025-08-13 | |
| 2024-03-31 | $5.56M 10-Q · filed 2025-08-13 | $13.66M derived: sum of 2 quarters · filed 2025-08-13 | ||
| 2023-12-31 | $8.10M 10-Q · filed 2025-08-13 | |||
| 2023-09-30 | $28.22M 10-K · filed 2025-11-19 | |||
| 2023-06-30 | $7.00M 10-Q · filed 2024-08-07 | $14.36M derived: sum of 2 quarters · filed 2024-08-07 | $21.50M derived: sum of 3 quarters · filed 2024-08-07 | |
| 2023-03-31 | $7.36M 10-Q · filed 2024-08-07 | $14.50M derived: sum of 2 quarters · filed 2024-08-07 | ||
| 2022-12-31 | $7.14M 10-Q · filed 2024-08-07 | |||
| 2022-09-30 | $26.97M 10-K · filed 2024-11-27 | |||
| 2022-06-30 | $7.60M 10-Q · filed 2023-08-08 | $14.07M derived: sum of 2 quarters · filed 2023-08-08 | $20.14M derived: sum of 3 quarters · filed 2023-08-08 | |
| 2022-03-31 | $6.47M 10-Q · filed 2023-08-08 | $12.53M derived: sum of 2 quarters · filed 2023-08-08 | ||
| 2021-12-31 | $6.06M 10-Q · filed 2023-08-08 | |||
| 2021-09-30 | $20.99M 10-K · filed 2023-11-22 | |||
| 2021-06-30 | $5.47M 10-Q · filed 2022-08-08 | $10.76M derived: sum of 2 quarters · filed 2022-08-08 | $15.64M derived: sum of 3 quarters · filed 2022-08-08 | |
| 2021-03-31 | $5.28M 10-Q · filed 2022-08-08 | $10.16M derived: sum of 2 quarters · filed 2022-08-08 | ||
| 2020-12-31 | $4.88M 10-Q · filed 2022-08-08 | |||
| 2020-09-30 | $19.57M 10-K · filed 2022-11-23 | |||
| 2020-06-30 | $4.75M 10-Q · filed 2021-08-09 | $9.73M derived: sum of 2 quarters · filed 2021-08-09 | $14.83M derived: sum of 3 quarters · filed 2021-08-09 | |
| 2020-03-31 | $4.98M 10-Q · filed 2021-08-09 | $10.07M derived: sum of 2 quarters · filed 2021-08-09 | ||
| 2019-12-31 | $5.10M 10-Q · filed 2021-08-09 | |||
| 2019-09-30 | $19.23M 10-K · filed 2021-11-24 | |||
| 2019-06-30 | $4.16M 10-Q · filed 2020-08-10 | $8.87M derived: sum of 2 quarters · filed 2020-08-10 | $14.71M derived: sum of 3 quarters · filed 2020-08-10 | |
| 2019-03-31 | $4.71M 10-Q · filed 2020-08-10 | $10.55M derived: sum of 2 quarters · filed 2020-08-10 | ||
| 2018-12-31 | $5.84M 10-Q · filed 2020-08-10 | |||
| 2018-09-30 | $15.85M 10-K · filed 2020-11-25 | |||
| 2018-06-30 | $4.03M 10-Q · filed 2019-08-09 | $7.62M derived: sum of 2 quarters · filed 2019-08-09 | $11.73M derived: sum of 3 quarters · filed 2019-08-09 | |
| 2018-03-31 | $3.59M 10-Q · filed 2019-08-09 | $7.71M derived: sum of 2 quarters · filed 2019-08-09 | ||
| 2017-12-31 | $4.12M 10-Q · filed 2019-08-09 | |||
| 2017-09-30 | $13.07M 10-K · filed 2019-11-27 | |||
| 2016-09-30 | $9.35M 10-K · filed 2018-11-29 | |||
| 2015-09-30 | $5.84M 10-K · filed 2017-12-11 | |||
| 2014-09-30 | $2.68M 10-K · filed 2016-12-09 | |||
| 2013-09-30 | $1.06M 10-K · filed 2015-12-11 | |||
| 2012-09-30 | $424.00K 10-K · filed 2014-12-11 | |||
| 2011-09-30 | $225.00K 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |